Excellus BlueCross BlueShieldCommercial · Billing Codes · Skin (Dermatology) · NY · Wound Care, Plastic Surgery, Podiatry +1 moreHigh impact
Bioengineered Tissue Products for Wound Treatment and Surgical Interventions 7.01.35
Effective date
Aug 20, 2026
Identified
Jun 20, 2026
Summary
Excellus BlueCross BlueShield medical policy 7.01.35, Bioengineered Tissue Products for Wound Treatment and Surgical Interventions, has a current effective date of August 20, 2026. The 08/20/26 annual review added CPT codes 15011-15018, and the 10/22/26 off-cycle update added HCPCS codes A2041-A2050, G0681-G0684, Q4243, Q4398-Q4429, Q4431-Q4433 and Q4435-Q4440 while removing termed HCPCS codes C5271-C5278, Q4100 and Q4106. Policy intent is unchanged for both updates.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.
01Already effective August 20, 2026: Billing team, when billing these codes, confirm that the product is used in accordance with its FDA product approval and that the policy criteria are met.
02Codes marked (E/I) are experimental/investigational, and all other bioengineered tissue products are considered investigational for any indication.
03For a product used off label, documentation of a shared decision-making process and informed consent is required.
04Reinitiated treatment on the same wound site less than one year after successful treatment is considered treatment failure and not medically appropriate.
05Codes may not be covered under all circumstances.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.